Macquarie Group’s Epizyme, Inc EPZM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-203,200
Closed -$299K 2567
2022
Q2
$299K Sell
203,200
-2,631
-1% -$1.93K ﹤0.01% 1648
2022
Q1
$237 Hold
205,831
﹤0.01% 1778
2021
Q4
$515K Hold
205,831
﹤0.01% 1650
2021
Q3
$1.05M Hold
205,831
﹤0.01% 1571
2021
Q2
$1.71M Hold
205,831
﹤0.01% 1457
2021
Q1
$1.79M Sell
205,831
-1,049
-0.5% -$10.9K ﹤0.01% 1237
2020
Q4
$2.25M Hold
206,880
﹤0.01% 1067
2020
Q3
$2.47M Hold
206,880
﹤0.01% 986
2020
Q2
$3.32M Sell
206,880
-711
-0.3% -$12.4K 0.01% 884
2020
Q1
$3.22M Buy
207,591
+4,391
+2% +$94.3K 0.01% 814
2019
Q4
$5M Hold
203,200
0.01% 808
2019
Q3
$2.1M Hold
203,200
﹤0.01% 1012
2019
Q2
$2.55M Hold
203,200
﹤0.01% 957
2019
Q1
$2.52M Hold
203,200
﹤0.01% 938
2018
Q4
$1.25M Hold
203,200
﹤0.01% 1089
2018
Q3
$2.15M Sell
203,200
-40,661
-17% -$464K ﹤0.01% 991
2018
Q2
$3.3M Buy
243,861
+1,740
+0.7% +$27.1K 0.01% 864
2018
Q1
$4.3M Buy
242,121
+159,636
+194% +$2.7M 0.01% 793
2017
Q4
$1.03M Buy
82,485
+41,385
+101% +$602K ﹤0.01% 1235
2017
Q3
$783K Buy
41,100
+21,100
+106% +$322K ﹤0.01% 1299
2017
Q2
$302K Hold
20,000
﹤0.01% 1372
2017
Q1
$343K Hold
20,000
﹤0.01% 1374
2016
Q4
$242K Hold
20,000
﹤0.01% 1410
2016
Q3
$197K Sell
20,000
-20,000
-50% -$183K ﹤0.01% 1411
2016
Q2
$410K Buy
40,000
+20,000
+100% +$223K ﹤0.01% 1393
2016
Q1
$242K Hold
20,000
﹤0.01% 1331
2015
Q4
$320K Hold
20,000
﹤0.01% 1264
2015
Q3
$257K Hold
20,000
﹤0.01% 1361
2015
Q2
$480K Hold
20,000
﹤0.01% 1302
2015
Q1
$376K Hold
20,000
﹤0.01% 1325
2014
Q4
$377K Hold
20,000
﹤0.01% 1316
2014
Q3
$542K Hold
20,000
﹤0.01% 1244
2014
Q2
$622K Hold
20,000
﹤0.01% 1272
2014
Q1
$455K Hold
20,000
﹤0.01% 1304
2013
Q4
$416K Hold
20,000
﹤0.01% 1292
2013
Q3
$803K Hold
20,000
﹤0.01% 1217
2013
Q2
$563K Buy
+20,000
New +$514K ﹤0.01% 1263

Other funds holding EPZM

Macquarie Group's EPZM Position: Q3 2022 in Review

Macquarie Group sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 203,200 shares — an estimated $299K sold.

Macquarie Group first reported a position in EPZM in Q2 2013 and held it in 37 quarters. The position peaked at $5M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • Macquarie Group reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 203,200 Epizyme, Inc shares in Q3 2022, an estimated $299K.
  • Macquarie Group first reported a position in Epizyme, Inc in Q2 2013 and held it in 37 quarters.
  • Macquarie Group's Epizyme, Inc position peaked at $5M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.